Fecal Microbiome Spatial Biomarkers for Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating the fecal microbiome lack effective biomarkers to improve patient selection for therapeutic interventions, leading to suboptimal response rates in complementary microbiome therapies.
Innovation Solution
A method for spatial characterization of the fecal microbiome through imaging and data processing to identify biomarkers, including microbial spatial structure, location, intensity, and interaction, which can differentiate between healthy and diseased states and treatment responders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If traditional microbiome evaluation methods (sequencing, culture, qPCR) are used, then microbiome composition can be measured, but spatial information and structural characteristics are lost
Solution Approach 1:
The patent transitions from one-dimensional compositional data (taxonomic abundance) to two-dimensional spatial information by implementing imaging-based microbiome analysis. This allows visualization and measurement of microbial spatial distribution, clustering patterns, and architectural structures within the microbiome community, recovering the spatial dimension that was lost in traditional sequencing methods.
Solution Approach 2:
The patent introduces spatial biomarkers as intermediary measures that bridge traditional compositional analysis and functional outcomes. These spatial characteristics serve as mediators that connect microbial community structure to treatment response, enabling more precise patient stratification without requiring complete reconstruction of the entire microbiome ecosystem.
2Reliability
If comprehensive spatial characterization is implemented, then treatment selection accuracy is improved, but method complexity increases
Solution Approach 1:
The patent extracts specific spatial biomarkers (clustering coefficients, distribution patterns, architectural features) from the complex microbiome ecosystem. By focusing on these discrete, quantifiable spatial characteristics rather than attempting to characterize the entire microbiome in detail, the method achieves reliable treatment prediction while maintaining practical feasibility.
Solution Approach 2:
The patent transforms the microbiome evaluation from compositional parameters (taxonomic abundance) to spatial parameters (distribution patterns, clustering metrics, spatial architecture). This parameter transformation enables more accurate treatment selection by capturing functional organizational principles of the microbiome that are independent of specific taxonomic composition.
3Reliability
If spatial biomarkers are used for patient stratification, then treatment response prediction is improved, but current lack of biomarkers limits effectiveness
Solution Approach 1:
The patent performs preliminary spatial characterization of the microbiome before treatment administration. By measuring spatial biomarkers in baseline samples, the method enables prospective patient stratification and treatment selection, allowing clinicians to choose the most appropriate therapy based on pre-treatment spatial microbiome architecture rather than relying on incomplete compositional data.
Data Source
AI summary
Disclosed herein is a method of evaluating the fecal microbiome of a subject comprising determining a spatial characterization of the fecal microbiome.